Canaccord Genuity Reiterates Buy on Avanir (AVNR) as Drug Sales Ramp

November 28, 2012 2:23 PM EST
Get Alerts AVNR Hot Sheet
Price: $16.96 --0%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade AVNR Now!
Join SI Premium – FREE
Canaccord Genuity maintained a Buy on Avanir Pharmaceuticals (NASDAQ: AVNR) with a price target of $6.00 after the company reported drug sales that beat estimates. Nuedexta gross sales came in a $15.4 million, beating consensus views of $14.8 million.

Commenting on the developments, analysts Ritu Baral said, "Recent sales trends continue to appear steady, and we foresee continued sales ramp in 2013."

Canaccord Genuity's $6 target on Avanir Pharmaceuticals (NASDAQ: AVNR) is based on a sum-of- the-parts analysis.

For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.

Shares of Avanir Pharmaceuticals closed at $2.66 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Canaccord Genuity

Add Your Comment